|
|
|
 |
Now
Available as Part of CHI's
Network of Affiliated
Reports |
 |
|
|
|
|
|
Commercial Insight: Cardiovascular and metabolic market overview Diabetes to the fore as generics hit primary care markets
ABOUT DATAMONITOR HEALTHCARE 2
About the cardiovascular pharmaceutical analysis team 2
CHAPTER 1 EXECUTIVE SUMMARY 3
Scope of the analysis 3
Datamonitor insight into
the cardiovascular market 3
Related reports 5
Upcoming reports 6
CHAPTER 2 MARKET OVERVIEW AND DYNAMICS 8
Seven major markets 8
Regional markets 11
US 11
Japan 12
5EU 13
Cardiovascular and metabolic markets by disease area 14
Seven major markets 14
Regional markets 16
US 16
Japan 17
5EU 18
Disease focus by mechanism of action 24
Diabetes 24
US 27
Japan 29
5EU 31
Dyslipidemia 32
US 34
Japan 36
5EU 37
Hypertension 40
US 42
Japan 44
5EU 46
Thrombosis 48
US 50
Japan 52
5EU 54
CHAPTER 3 MARKET FORECASTS 57
Seven major markets 57
Regional markets 61
US 61
Japan 62
5EU 63
Cardiovascular and metabolic market by disease area 65
Seven major markets 65
Regional markets 68
US 68
Japan 68
5EU 69
Disease focus by mechanism of action 79
Diabetes 79
US 82
Japan 83
5EU 85
Dyslipidemia 87
US 89
Japan 90
5EU 92
Hypertension 93
US 95
Japan 97
5EU 98
Thrombosis 101
US 104
Japan 105
5EU 106
CHAPTER 4 MARKET ANALYSIS 108
Leading cardiovascular and metabolic brands 108
Leading cardiovascular and metabolic active agents 111
Company portfolio assessment 114
The top 10 cardiovascular and metabolic companies, 2007 114
Pfizer 114
Sanofi-Aventis 116
Novartis 118
Merck & Co 119
Bristol-Myers Squibb 122
Takeda 123
GlaxoSmithKline 124
AstraZeneca 125
Novo Nordisk 126
Schering-Plough 126
Geographical distribution 128
Company vulnerability 130
The forecast top 10 cardiovascular and metabolic companies,
2004-2017 133
APPENDIX A - MARKET ASSUMPTIONS 137
Data definitions, limitations and assumptions 137
Standard units 137
Japanese market data 137
Derivation of sales forecasts and pricing trends 137
Forecasts 138
Forecast methodology 138
Datamonitor reports 138
APPENDIX B -MARKET FORECAST DATA 140
Seven major markets 140
Regional markets 159
US 159
Japan 167
5EU 174
France 187
Germany 194
Italy 202
Spain 209
UK 216
APPENDIX C 224
Report methodology 224
About Datamonitor 224
About Datamonitor Healthcare 224
Disclaimer 226
List of Tables
Table 1: Top 25 cardiovascular and metabolic brands in
the seven major markets, 2004-2017 110
Table 2: Top 25 cardiovascular and metabolic active agents in
the seven major markets, 2004-2017 113
Table 3: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the seven major markets ($
million), 2007-2017 (Part I) 140
Table 4: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the seven major markets ($
million), 2007-2017 (Part II) 144
Table 5: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the seven major markets ($
million), 2007-2017 (Part III) 148
Table 6: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the seven major markets ($
million), 2007-2017 (Part IV) 152
Table 7: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the seven major markets ($
million), 2007-2017 (Part V) 156
Table 8: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the US ($ million),
2007-2017 (Part I) 159
Table 9: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the US ($ million),
2007-2017 (Part II) 163
Table 10: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the Japan ($ million),
2007-2017 (Part I) 167
Table 11: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the Japan ($ million),
2007-2017 (Part II) 170
Table 12: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the 5EU ($ million),
2007-2017 (Part I) 174
Table 13: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the 5EU ($ million),
2007-2017 (Part II) 178
Table 14: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the 5EU ($ million),
2007-2017 (Part III) 182
Table 15: Sales forecast for the major cardiovascular and
metabolic brands and active agents in France ($ million),
2007-2017 (Part I) 187
Table 16: Sales forecast for the major cardiovascular and
metabolic brands and active agents in France ($ million),
2007-2017 (Part II) 191
Table 17: Sales forecast for the major cardiovascular and
metabolic brands and active agents in Germany ($ million),
2007-2017 194
Table 18: Sales forecast for the major cardiovascular and
metabolic brands and active agents in Italy ($ million),
2007-2017 202
Table 19: Sales forecast for the major cardiovascular and
metabolic brands and active agents in Spain ($ million),
2007-2017 209
Table 20: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the UK ($ million),
2007-2017 (Part I) 216
Table 21: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the UK ($ million),
2007-2017 (Part II) 219
Table 22: Sales forecast for the major cardiovascular and
metabolic brands and active agents in the UK ($ million),
2007-2017 (Part III) 222
List of Figures
Figure 1: Cardiovascular and metabolic sales ($) and
standard units (SU) sold in the seven major markets, 2004-07 8
Figure 2: Total cardiovascular sales and sales growth in the
seven major markets, 2004-07 9
Figure 3: Geographical distribution of cardiovascular sales in
the seven major markets by value, 2004-07 10
Figure 4: Geographical distribution of cardiovascular units sold
(SU) in the seven major markets by volume, 2004-07 10
Figure 5: Total cardiovascular sales and sales growth in the US,
2004-07 12
Figure 6: Total cardiovascular sales and sales growth in Japan,
2004-07 13
Figure 7: Total cardiovascular sales and sales growth in the
5EU, 2004-07 14
Figure 8: Cardiovascular and metabolic sales in the seven major
markets by disease area, 2007 15
Figure 9: Cardiovascular and metabolic standard units (SU) sold
in the seven major markets by disease area, 2007 16
Figure 10: Cardiovascular and metabolic sales in the US market
by value ($ billion) by disease area, 2004-07 17
Figure 11: Cardiovascular and metabolic sales in Japan by value
($ billion) by disease area, 2004-07 18
Figure 12: Cardiovascular and metabolic sales in the 5EU markets
by value ($ billion) by disease area, 2004-07 19
Figure 13: Cardiovascular and metabolic sales in France by value
($ billion) by disease area, 2004-07 20
Figure 14: Cardiovascular and metabolic sales in Germany by
value ($ billion) by disease area, 2004-07 21
Figure 15: Cardiovascular and metabolic sales in Italy by value
($ billion) by disease area, 2004-07 22
Figure 16: Cardiovascular and metabolic sales in Spain by value
($ billion) by disease area, 2004-07 23
Figure 17: Cardiovascular and metabolic sales in the UK by value
($ billion) by disease area, 2004-07 24
Figure 18: Sales ($) of the leading mechanisms of action in the
diabetes market in the seven major markets, 2004-07 26
Figure 19: Use (SU sold) of the leading mechanisms of action in
the diabetes market in the seven major markets, 2004-07 26
Figure 20: Sales ($) of the leading mechanisms of action in the
diabetes market in the US, 2004-07 28
Figure 21: Use (SU sold) of the leading mechanisms of action in
the diabetes market in the US, 2004-07 28
Figure 22: Sales ($) of the leading mechanisms of action in the
diabetes market in Japan, 2004-07 30
Figure 23: Use (SU sold) of the leading mechanisms of action in
the diabetes market in Japan, 2004-07 30
Figure 24: Sales ($) of the leading mechanisms of action in the
diabetes market in the 5EU, 2004-07 31
Figure 25: Use (SU sold) of the leading mechanisms of action in
the diabetes market in the 5EU, 2004-07 32
Figure 26: Sales ($) of the leading mechanisms of action in the
dyslipidemia market in the seven major markets, 2004-07 33
Figure 27: Use (SU sold) of the leading mechanisms of action in
the dyslipidemia market in the seven major markets, 2004-07 33
Figure 28: Sales ($) of the leading mechanisms of action in the
dyslipidemia market in the US, 2004-07 35
Figure 29: Use (SU sold) of the leading mechanisms of action in
the dyslipidemia market in the US, 2004-07 35
Figure 30: Sales ($) of the leading mechanisms of action in the
dyslipidemia market in Japan, 2004-07 36
Figure 31: Use (SU sold) of the leading mechanisms of action in
the dyslipidemia market in Japan, 2004-07 37
Figure 32: Sales ($) of the leading mechanisms of action in the
dyslipidemia market in the 5EU, 2004-07 38
Figure 33: Use (SU sold) of the leading mechanisms of action in
the dyslipidemia market in the 5EU, 2004-07 39
Figure 34: Sales ($) of the leading mechanisms of action in the
hypertension market in the seven major markets, 2004-07 40
Figure 35: Use (SU sold) of the leading mechanisms of action in
the hypertension market in the seven major markets, 2004-07 41
Figure 36: Sales ($) of the leading mechanisms of action in the
hypertension market in the US, 2004-07 43
Figure 37: Use (SU sold) of the leading mechanisms of action in
the hypertension market in the US, 2004-07 44
Figure 38: Sales ($) of the leading mechanisms of action in the
hypertension market in Japan, 2004-07 45
Figure 39: Use (SU sold) of the leading mechanisms of action in
the hypertension market in Japan, 2004-07 46
Figure 40: Sales ($) of the leading mechanisms of action in the
hypertension market in the 5EU, 2004-07 47
Figure 41: Use (SU sold) of the leading mechanisms of action in
the hypertension market in the 5EU, 2004-07 48
Figure 42: Sales ($) of the leading mechanisms of action in the
antithrombotics market in the seven major markets, 2004-07 49
Figure 43: Use (SU sold) of the leading mechanisms of action in
the antithrombotics market in the seven major markets, 2004-07
50
Figure 44: Sales ($) of the leading mechanisms of action in the
antithrombotics market in the US, 2004-07 51
Figure 45: Use (SU sold) of the leading mechanisms of action in
the antithrombotics market in the US, 2004-07 52
Figure 46: Sales ($) of the leading mechanisms of action in the
antithrombotics market in Japan, 2004-07 53
Figure 47: Use (SU sold) of the leading mechanisms of action in
the antithrombotics market in Japan, 2004-07 54
Figure 48: Sales ($) of the leading mechanisms of action in the
antithrombotics market in the 5EU, 2004-07 55
Figure 49: Use (SU sold) of the leading mechanisms of action in
the antithrombotics market in the 5EU, 2004-07 56
Figure 50: Forecast cardiovascular and metabolic sales ($) and
standard units (SU) sold in the seven major markets, 2007-2017
58
Figure 51: Forecast total cardiovascular and metabolic sales and
sales growth in the seven major markets, 2007-2017 59
Figure 52: Geographical distribution of forecast cardiovascular
and metabolic sales ($) in the seven major markets, 2007-2017 60
Figure 53: Geographical distribution of forecast cardiovascular
and metabolic standard unit
|
|